23 December 2023 - The CRL is related to deficiencies identified at a third-party manufacturing facility following an inspection but are ...
22 December 2023 - Submission based on HERTHENA-Lung01 results showing patritumab deruxtecan demonstrated clinically meaningful and durable responses in patients ...
22 December 2023 - Sarepta has also submitted the EMBARK post-marketing requirement to the FDA seeking conversion of the Elevidys accelerated ...
22 December 2023 - Zealand Pharma today announced the submission of a new drug application to the US FDA for glepaglutide, ...
21 December 2023 - Submissions supported by data from landmark Phase 3 MARIPOSA study, which showed statistically significant and clinically meaningful ...
21 December 2023 - Merck today announced that the US FDA has issued a complete response letter regarding Merck’s new drug ...
19 December 2023 - Interim analysis results from first of its kind Phase 3 OUtMATCH study showed Xolair significantly increased the ...
19 December 2023 - The 21 serotypes covered by V116 are responsible for approximately 83% of invasive pneumococcal disease in ...
19 December 2023 - Telix today announces that it has submitted its biologics license application to the United States US FDA ...
18 December 2023 - FDA did not state any concerns about the clinical data package, safety, or labeling for the approvability ...
15 December 2023 - New drug application is supported by data evaluating seladelpar efficacy and safety in over 500 patients. ...
14 December 2023 - These regulatory milestones bring CSL one step closer to delivering on our promise to patients with ...
13 December 2023 - FDA target action date is 12 June 2024. ...
12 December 2023 - Filing marks first NDA submission for any psychedelic-assisted therapy. ...
12 December 2023 - BLA supported by results from Phase 2/3 clinical trial and outcomes of real-world use of the human ...